Study protocol: Australasian Registry of Severe Cutaneous Adverse Reactions (AUS-SCAR)
Introduction Severe cutaneous adverse reactions (SCAR) are a group of T cell-mediated hypersensitivities associated with significant morbidity, mortality and hospital costs. Clinical phenotypes include Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia...
Published in: | BMJ Open |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BMJ
2022
|
Subjects: | |
Online Access: | http://dx.doi.org/10.1136/bmjopen-2021-055906 https://syndication.highwire.org/content/doi/10.1136/bmjopen-2021-055906 |
id |
crjcrbmj:10.1136/bmjopen-2021-055906 |
---|---|
record_format |
openpolar |
spelling |
crjcrbmj:10.1136/bmjopen-2021-055906 2024-09-15T18:33:57+00:00 Study protocol: Australasian Registry of Severe Cutaneous Adverse Reactions (AUS-SCAR) James, Fiona Goh, Michelle S Y Mouhtouris, Effie Vogrin, Sara Chua, Kyra Y L Holmes, Natasha E Awad, Andrew Copaescu, Ana-Maria De Luca, Joseph F Zubrinich, Celia Gin, Douglas Cleland, Heather Douglas, Abby Kern, Johannes S Katelaris, Constance H Thien, Francis Barnes, Sara Yun, James Tong, Winnie Smith, William B Carr, Andrew Anderson, Tara Legg, Amy Bourke, Jack Mackay, Laura K Aung, Ar Kar Phillips, Elizabeth J Trubiano, Jason 2022 http://dx.doi.org/10.1136/bmjopen-2021-055906 https://syndication.highwire.org/content/doi/10.1136/bmjopen-2021-055906 en eng BMJ http://creativecommons.org/licenses/by-nc/4.0/ BMJ Open volume 12, issue 8, page e055906 ISSN 2044-6055 2044-6055 journal-article 2022 crjcrbmj https://doi.org/10.1136/bmjopen-2021-055906 2024-08-29T04:10:16Z Introduction Severe cutaneous adverse reactions (SCAR) are a group of T cell-mediated hypersensitivities associated with significant morbidity, mortality and hospital costs. Clinical phenotypes include Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalised exanthematous pustulosis (AGEP). In this Australasian, multicentre, prospective registry, we plan to examine the clinical presentation, drug causality, genomic predictors, potential diagnostic approaches, treatments and long-term outcomes of SCAR in Australia and New Zealand. Methods and analysis Adult and adolescent patients with SCAR including SJS, TEN, DRESS, AGEP and another T cell-mediated hypersensitivity, generalised bullous fixed drug eruption, will be prospectively recruited. A waiver of consent has been granted for some sites to retrospectively include cases which result in early mortality. DNA will be collected for all prospective cases. Blood, blister fluid and skin biopsy sampling is optional and subject to patient consent and site capacity. To develop culprit drug identification and prevention, genomic testing will be performed to confirm human leukocyte antigen (HLA) type and ex vivo testing will be performed via interferon-γ release enzyme linked immunospot assay using collected peripheral blood mononuclear cells. The long-term outcomes of SCAR will be investigated with a 12-month quality of life survey and examination of prescribing and mortality data. Ethics and dissemination This study was reviewed and approved by the Austin Health Human Research Ethics Committee (HREC/50791/Austin-19). Results will be published in peer-reviewed journals and presented at relevant conferences. Trial registration number Australian New Zealand Clinical Trials Registry (ACTRN12619000241134). Article in Journal/Newspaper SCAR The BMJ BMJ Open 12 8 e055906 |
institution |
Open Polar |
collection |
The BMJ |
op_collection_id |
crjcrbmj |
language |
English |
description |
Introduction Severe cutaneous adverse reactions (SCAR) are a group of T cell-mediated hypersensitivities associated with significant morbidity, mortality and hospital costs. Clinical phenotypes include Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalised exanthematous pustulosis (AGEP). In this Australasian, multicentre, prospective registry, we plan to examine the clinical presentation, drug causality, genomic predictors, potential diagnostic approaches, treatments and long-term outcomes of SCAR in Australia and New Zealand. Methods and analysis Adult and adolescent patients with SCAR including SJS, TEN, DRESS, AGEP and another T cell-mediated hypersensitivity, generalised bullous fixed drug eruption, will be prospectively recruited. A waiver of consent has been granted for some sites to retrospectively include cases which result in early mortality. DNA will be collected for all prospective cases. Blood, blister fluid and skin biopsy sampling is optional and subject to patient consent and site capacity. To develop culprit drug identification and prevention, genomic testing will be performed to confirm human leukocyte antigen (HLA) type and ex vivo testing will be performed via interferon-γ release enzyme linked immunospot assay using collected peripheral blood mononuclear cells. The long-term outcomes of SCAR will be investigated with a 12-month quality of life survey and examination of prescribing and mortality data. Ethics and dissemination This study was reviewed and approved by the Austin Health Human Research Ethics Committee (HREC/50791/Austin-19). Results will be published in peer-reviewed journals and presented at relevant conferences. Trial registration number Australian New Zealand Clinical Trials Registry (ACTRN12619000241134). |
format |
Article in Journal/Newspaper |
author |
James, Fiona Goh, Michelle S Y Mouhtouris, Effie Vogrin, Sara Chua, Kyra Y L Holmes, Natasha E Awad, Andrew Copaescu, Ana-Maria De Luca, Joseph F Zubrinich, Celia Gin, Douglas Cleland, Heather Douglas, Abby Kern, Johannes S Katelaris, Constance H Thien, Francis Barnes, Sara Yun, James Tong, Winnie Smith, William B Carr, Andrew Anderson, Tara Legg, Amy Bourke, Jack Mackay, Laura K Aung, Ar Kar Phillips, Elizabeth J Trubiano, Jason |
spellingShingle |
James, Fiona Goh, Michelle S Y Mouhtouris, Effie Vogrin, Sara Chua, Kyra Y L Holmes, Natasha E Awad, Andrew Copaescu, Ana-Maria De Luca, Joseph F Zubrinich, Celia Gin, Douglas Cleland, Heather Douglas, Abby Kern, Johannes S Katelaris, Constance H Thien, Francis Barnes, Sara Yun, James Tong, Winnie Smith, William B Carr, Andrew Anderson, Tara Legg, Amy Bourke, Jack Mackay, Laura K Aung, Ar Kar Phillips, Elizabeth J Trubiano, Jason Study protocol: Australasian Registry of Severe Cutaneous Adverse Reactions (AUS-SCAR) |
author_facet |
James, Fiona Goh, Michelle S Y Mouhtouris, Effie Vogrin, Sara Chua, Kyra Y L Holmes, Natasha E Awad, Andrew Copaescu, Ana-Maria De Luca, Joseph F Zubrinich, Celia Gin, Douglas Cleland, Heather Douglas, Abby Kern, Johannes S Katelaris, Constance H Thien, Francis Barnes, Sara Yun, James Tong, Winnie Smith, William B Carr, Andrew Anderson, Tara Legg, Amy Bourke, Jack Mackay, Laura K Aung, Ar Kar Phillips, Elizabeth J Trubiano, Jason |
author_sort |
James, Fiona |
title |
Study protocol: Australasian Registry of Severe Cutaneous Adverse Reactions (AUS-SCAR) |
title_short |
Study protocol: Australasian Registry of Severe Cutaneous Adverse Reactions (AUS-SCAR) |
title_full |
Study protocol: Australasian Registry of Severe Cutaneous Adverse Reactions (AUS-SCAR) |
title_fullStr |
Study protocol: Australasian Registry of Severe Cutaneous Adverse Reactions (AUS-SCAR) |
title_full_unstemmed |
Study protocol: Australasian Registry of Severe Cutaneous Adverse Reactions (AUS-SCAR) |
title_sort |
study protocol: australasian registry of severe cutaneous adverse reactions (aus-scar) |
publisher |
BMJ |
publishDate |
2022 |
url |
http://dx.doi.org/10.1136/bmjopen-2021-055906 https://syndication.highwire.org/content/doi/10.1136/bmjopen-2021-055906 |
genre |
SCAR |
genre_facet |
SCAR |
op_source |
BMJ Open volume 12, issue 8, page e055906 ISSN 2044-6055 2044-6055 |
op_rights |
http://creativecommons.org/licenses/by-nc/4.0/ |
op_doi |
https://doi.org/10.1136/bmjopen-2021-055906 |
container_title |
BMJ Open |
container_volume |
12 |
container_issue |
8 |
container_start_page |
e055906 |
_version_ |
1810475676130607104 |